In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

From Iran To The US: From Scientist To Entrepreneur

Interview With Bioniz CEO Nazli Azimi

Executive Summary

California-based Bioniz’s lead candidate for cutaneous T-cell lymphoma has been granted orphan drug designation and expects to begin Phase III trials in the second half of 2021. CEO Nazli Azimi explains the science, which originated from her research in academia, and talks about her entrepreneurial journey.

You may also be interested in...



Deal Watch: AbbVie Adds Neuroscience Heft With Syndesi Acquisition

AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.

Biotech Foundations: Networks And Lab Space Are As Crucial As Funding

BioInnovation Institute chief business officer Bobby Soni shares how the life sciences incubator sources entrepreneurs and science globally, and the range of tools it provides to translate this into commercially viable companies. 

Lithuania Caps Off Decade Of Growth With Stellar 2020

Lithuania’s life sciences sector has harnessed the country’s talent, infrastructure and government support to realize a decade of unprecedented growth. With the industry now maturing, can the Baltic state overcome challenges to become a significant European player?

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

IV124788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel